Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase
September 6, 2023Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase
Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
September 5, 2023Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
FDA approves new ADHD and BED generics
September 1, 2023Medical Communications BED, FDA, Pharmacy, generic medicines
The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …
First patient dosed in phase 1 study for chronic hepatitis B treatment
August 31, 2023Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B
ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
Twist Bioscience and Ono Pharmaceutical enter agreement for discovery of novel antibodies
August 31, 2023Research and Development Immunology, Ono Pharmaceutical, Twist Bioscience, antibodies, autoimmune diseases
Twist Bioscience has announced that it has entered a drug discovery agreement with Ono Pharmaceutical for the discovery and development …
Novo Nordisk acquires Embark Biotech and its lead metabolic programme
August 31, 2023Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …
CN Bio introduces Dr Tomasz Kostrzewski as new chief scientific officer
August 31, 2023Business Services CN Bio, CSO, Dr Tomasz Kostrzewski, Microbiology
On 30August 2023, CN Bio announced the appointment of Dr Tomasz Kostrzewski as chief scientific officer (CSO) – a new …
Merck’s Keytruda approved by EC for gastric cancer
August 30, 2023Research and Development EC, Merck, Oncology, gastric cancer, keytruda
Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …
FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS
August 30, 2023Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …
EC approves Roche’s Evrysdi for babies under two months with SMA
August 30, 2023Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy
Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …
FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab
August 29, 2023Research and Development FDA, Faron, ODD, Oncology, leukemia
Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …
Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan
August 29, 2023Sales and Marketing Elahere, Immunogen, Oncology, Takeda
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …
Janssen submits sNDA to FDA for full approval of Balversa
August 29, 2023Research and Development Balversa, FDA, Janssen, Oncology
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
August 25, 2023Medical Communications FDA, MS, Neurology, Sandoz
Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …
Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis
August 25, 2023Medical Communications Demodex blepharitis, FDA, Opthalmology, Tarsus Pharmaceuticals, eyedrops
Tarsus Pharmaceuticals has announced that the US Food and Drug Administration (FDA) approved its drug Xdemvy (lotillaner ophthalmic solution) 0.25% …
Lynparza granted approval to treat prostate cancer in Japan
August 25, 2023Research and Development Merck, Oncology, astra zeneca, prostate cancer
AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
